Introduction
Ets-1 is the founding member of the ETS family of transcription factors, which is defined by a conserved DNA binding domain spanning 85 amino acids that forms a winged helix-turnhelix structural motif. Through this domain the Ets proteins bind to specific purine rich DNA sequences containing a conserved GGA core and regulate a wide range of biological processes 1 .
The human Ets-1 gene produces two major protein isoforms, a 51 kDa protein (p51 Ets-1) and a 42 kDa protein (p42 Ets-1) [2] [3] [4] [5] . Ets-1 is expressed in a variety of tissues and in several cases the p42 Ets-1 is co-expressed with full-length p51 Ets-1. p51 and p42 Ets-1 have common and diverse physical properties allowing for both functional redundancy and isoform-specific activity 2 . Shared domains include the DNA binding and the pointed transactivation domain.
p42 Ets-1 lacks exon VII 4 which encodes an autoinhibitory module 6 that regulates Ets-1 DNA binding activity. Co-operative binding with other proteins counteracts autoinhibition modulating Ets-1 DNA binding affinity 2, 7 . Ets-1 activity can also be regulated by phosphorylation and depending on the site of phosphorylation, Ets-1 function can be either increased or inhibited. Phosphorylation of threonine 38 (T38) within the pointed domain by ERK1/2 activates Ets-1 8, 9 , whereas phosphorylation of serines S251, S257, S282, S285 (4S) within the N-terminal part of exon VII by CaMKII or MLCK, stabilizes and reinforces the autoinhibitory module lowering DNA affinity [10] [11] [12] [13] . Thus, the splice variant isoform lacking the inhibitory module may function differentially from the full-length protein.
Ets-1 plays an important role in cell proliferation, apoptosis, transformation, differentiation, angiogenesis and hematopoiesis. Ets-1 expression is induced in a variety of human tumors, and its level has been associated with the grade of malignancy and prognosis in several types of tumors including breast, lung and colorectal cancer 14 . In addition to advanced solid tumors, high Ets-1 was also found in leukemic T cells and seems an attractive candidate oncogene involved in the 11q23 amplifications detected in some adult patients with acute 4 myeloid leukemia (AML) with complex karyotypes [15] [16] [17] [18] .
In normal hematopoiesis Ets-1 is involved in the regulation of lymphopoiesis 19, 20 , in the development of natural killer cells 21 and in megakaryopoiesis 22, 23 . Ets-1 is involved in the regulation of eosinophil-specific promoter 24 , but no data are currently available on the role of Ets-1, if any, during granulocytic differentiation.
The human NB4 promyelocytic 25 and HL60 myeloblastic 26 The retroviral vector Pinco/IRES-GFP (Pi) containing Ets-1 cDNA was previously described 23 . The Ets-1 transdominant negative mutant (TM) 29 was cloned into the same Pi vector.
Infectious particles were produced as previously described 23 and cells were infected by the spin inoculation method 32 . Concisely, cells were subjected to 2 infection cycles: for each cycle cells were plated at 10 5 /ml in retroviral supernatant (>10 6 pfu/ml) in the presence of 4μg/ml polybrene, and centrifuged at 1800 rpm for 45 min at 32°C. Thereafter, cells were incubated at 37°C 5% CO 2 for 1 h 15 min followed by plating in fresh medium. GFP-positive cells were sorted 48 h post-infection by flow cytometry using a FACSAria (Becton Dickinson, Franklin Lakes, NJ, USA).
For morphological analysis, cells were smeared on glass slides by cytospin centrifugation, stained with May-Grünwald-Giemsa and analyzed at 400x or 630x magnification under a microscope equipped with a digital camera (Eclipse 1000, Nikon, Tokio, Japan).
HPCs purification and granulocytic culture. Adult peripheral blood (PB) was obtained from buffy coats of blood donation units. CD34 + HPCs were isolated as previously described 33 . Briefly, human CD34 + cells were purified from PB by positive selection using the midi-MACS immunomagnetic separation system according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladabach, Germany). CD34 + progenitor cells were cultured in serum-free medium in the presence of 1U/ml IL-3, 0.1ng/ml GM-CSF combined with saturating level of G-CSF (500 U/ml) (PeproTech, Rocky Hill, NJ, USA). presence of both activating and inhibitory phosphorylation events has been already described in other cellular systems 34 .
Phosphorylation of 4S stabilizes the inhibitory module, thereby reducing the DNA binding affinity. To determine whether serine phosphorylations may account for a decreased Ets-1 binding activity, during ATRA-induced differentiation we performed electrophoretic-mobility shift assay (EMSA). We examined the binding activity of Ets-1 protein to 32 P-labeled synthetic double-stranded oligonucleotide containing a consensus binding motif for Ets-1. A specific Ets-1-DNA complex was clearly evidenced in untreated cells ( Figure 1D , lanes 1, 6, 7), whereas ATRA treatment markedly reduced Ets-1-DNA complex formation throughout the differentiation process ( Figure 1D , lanes 2-4). As expected 11 , alkaline phosphatase treatment of 48 hours treated NB4 whole cell extracts resulted in increased Ets-1 binding activity ( Figure 1D, lanes 8, 9) . Similar results were obtained during ATRA-induced differentiation of HL60 cells ( Figure 1E and data not shown).
These results indicated that ATRA treatment reduced Ets-1 protein expression and induced inhibitory phosphorylation of the remaining protein in a time-dependent manner.
We next analyzed the expression of Ets-1 in NB4.R2 and HL60R cells, which are resistant to ATRA-induced differentiation. In contrast to the ATRA-sensitive cells, treatment of NB4.R2 and HL60R cells with ATRA either did not decrease Ets-1 expression or induce Ets-1 phosphorylations size shift ( Figure 1F ).
Altogether these data indicated that Ets-1 down-modulation is part of the ATRA pathways leading to granulocytic differentiation. Altogether, these results confirmed that Ets-1 down-regulation is a relevant event for ATRAinduced granulocytic differentiation. However, since transcriptional suppression or siRNA knockdown are not "per se" sufficient to trigger the differentiation process, our data suggest that Ets-1 decrease contributes to and/or enhances ATRA-induced differentiation.
Ets-1 down-modulation is required for granulocytic differentiation and maturation of peripheral blood CD34 + hematopoietic progenitor cells (HPCs). We then investigated
whether down-modulation of Ets-1 expression is specific to ATRA-induced granulocytic differentiation or also takes place when cells were treated with other granulocytic differentiation-inducing agents. DMSO-induced granulocytic differentiation of NB4 cells ( Figure 5A ) was associated with down-regulation of Ets-1 ( Figure 5B) ; however, the rate at as Ets-2 1, 2 . Nevertheless, specific targeted inhibition of Ets-1 expression by siRNA resulted in a significant increase of granulocytic differentiation, thus demonstrating that a major role may be ascribed to Ets-1. Furthermore, upon ATRA treatment, the remaining p51 Ets-1 protein was phosphorylated within the inhibitory module in the exon VII domain, leading to stabilization of the inhibitory structure and strong reduction of Ets-1 DNA binding activity.
Interestingly, differentiating NB4 and HL60 cells, as well as normal CD34 + HPCs, did not express the p42 splice variant isoform lacking the inhibitory phosphorylation sites. This isoform is resistant to the negative regulation and confers the ability to p42 Ets-1 to form stable complexes with DNA.
The kinases that are able to phosphorylate the cluster of serines within the inhibitory module are calmodulin-dependent kinase II (CaMKII) [10] [11] [12] [13] and myosin light-chain kinase (MLCK) 13 , both of which mediate calcium-dependent phosphorylation. Calcium is an important cellular second messenger that can regulate cell proliferation, differentiation and apoptosis. In NB4
and HL60 cells, ATRA-dependent differentiation is enhanced via modulation of intracellular calcium homeostasis 38, 39 . Calcium-dependent inhibition of Ets-1 DNA binding could be part of a general mechanism to remove Ets-1 function from the cell during granulocytic differentiation.
Previous studies indicated that the active form of CaMKII decreases during ATRA-induced differentiation and pharmacological inhibition of CaMKII enhances ATRA-induced differentiation in these cellular systems 40, 41 . These observations indirectly indicated that CaMKII may not be involved in Ets-1 phosphorylation upon ATRA treatment. Thus MLCK or other kinases, over the CaMKII, seem to be involved in Ets-1 inactivation during granulocytic maturation. Further, it has to be considered that Ets-1 inactivation is not ATRAdependent, but generalizes to granulocytic differentiation.
In line with the down-modulation of Ets-1 protein levels and activity, we observed a parallel decreased expression of Ets-1 mRNA following up to 48 h ATRA treatment, while Ets-1 mRNA levels started increasing after 72 h of treatment. This up-regulation might be ascribed to the presence of a functional retinoic acid responsive element on the human Ets-1 promoter 42, 43 , but is not reflected in increased protein levels. The same trend was observed during granulocytic differentiation of CD34 + hematopoietic progenitor cells.
These data suggested that the difference between Ets-1 mRNA and protein levels in Ets-1 induced differentiation is worthy of comment. Our results showed that overexpression of full-length Ets-1 isoform slightly enhances rather than inhibits differentiation. This apparent paradox may be elicited by the changed levels of Ets-1 protein which may alter the spectrum of Ets-1 functions and modify the activity of Ets-1 containing complexes, resulting in aberrant activation of the differentiation program. Similarly, the increased apoptosis showed by Ets-1 overexpressing cells may be ascribed to unbalanced composition of Ets-1 containing complexes and/or abnormal Ets-1 activity.
However, we do not define here the molecular pathways and networks through which Ets-1 transcription factor acts in the various stages of granulocytic development. Considering the complexity of Ets-1 interactions, the variety of biological processes where it takes part and the number of potential targets, it is difficult to speculate on the molecular networks/pathways in which it might be involved. ).
Further studies are warranted to decipher the role of Ets-1 and its implication in myeloid cell maturation, and to understand how a deregulated Ets-1 expression triggers an apoptotic response while also blocking the differentiation process. 
